Safety and Efficacy of LCI699 for the treatment of Patients with Cushing's disease

Principal Investigator	Peter J. Snyder MD
Study Title:	Safety and Efficacy of LCI699 for the treatment of Patients with Cushing's disease
Purpose:	This study aims to confirm long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease.
Brief Description	This study involves 22 visits over a 48 week period. Period 1: To determine the most effective dose Period 2: To test the safety and effectiveness of the dose as determined in initial period Period 3: Subjects would be randomized to receive study mediction or placebo. Period 4: All subject would receive study drug. Option of an Extension Study for at least another year
Eligibility	-18 years or older -Diagnosis of Cushing's disease that is persistent or recurrent -Mean of 3 24 hour urine collections greater than 1.5 x the upper limit of normal
Compensation (if applicable)	$25 per visit to help cover the cost of transportation
Name	Eileen Markmann
Phone	(215) 898-5664
Email:	eileen.markmann@uphs.upenn.edu